FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSH	ΗP
--	----

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours ner resnonse.	0.5						

	Check this box if no longer subject to						
$\Box$	Section 16. Form 4 or Form 5 obligations may continue. See						
$\cup$	obligations may continue. See						
	Instruction 1(b).						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>USMAN NASSIM</u>					2. Issuer Name and Ticker or Trading Symbol <u>CATALYST BIOSCIENCES</u> , <u>INC.</u> [ CBIO ]							ck all application	able)	erson(s) to Issi 10% O	wner	
(Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 710					3. Date of Earliest Transaction (Month/Day/Year) 02/08/2021							X Officer (give title Other (specify below)  President & CEO				
(Street) SOUTH FRANCI	- C	A	94080		4. If Amendment, Date of Original Filed (Month/Day/Year) 02/10/2021					Line)	Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)									Person				
		Та	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired, Di	isposed o	of, or Be	neficially	Owned				
Date			action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.				Beneficia Owned Fe	s Form (D) o ollowing (I) (In		7. Nature of ndirect Beneficial Dwnership				
								Code V Amount (A) (D)		r Price	Transacti	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
			Table II - De (e.ç					uired, Dis , options,				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	kercise (Month/Day/Year) e of vative	3A. Deemed Execution Date, if any (Month/Day/Year	Code (	Transaction Code (Instr.		er of re ss I (A) sed str. 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	Amount or Number of Shares		(Instr. 4)	5)							
Stock Option (Right to Buy)	\$5.89	02/08/2021		A		140,000		(1)	02/08/2031	Common Stock	140,000	\$0.00	140,000	D		

. Award vests and will become exercisable monthly over 48 months, with 25% of the shares vesting on the 12-month anniversary of the date hereof, and the remainder vesting monthly thereafter at the rate of 1/48th of the total number of shares.

## Remarks:

The sole purpose of this amendment to the Form 4 filed on February 10, 2021, is to correct the vesting schedule.

/s/ Faisal Shawwa, Attorney-in-04/26/2021 Fact for Nassim Usman

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.